Related Experiment Video
Updated: Jun 22, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Bimekizumab as-needed dosing in patients with psoriasis: a case series
Carlota Abbad-Jaime De Aragón1,2, Emilio Berna-Rico1,2, Pedro Jaén1,2
1Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Introduction:
Despite significant advances in psoriasis treatment, off-label dosing studies of psoriasis biologic therapies are limited.
Materials And Methods:
In this retrospective case series, medical records from 28 patients with moderate-to-severe psoriasis treated with bimekizumab during 64-week period from May 2023 to October 2024 at the Psoriasis Unit of the Grupo Jaen (Madrid, Spain), were evaluated. Patients were managed with an off-label, as-needed, dosing strategy, with all patients initially receiving two 320 mg doses of bimekizumab at Weeks 0 and 4; subsequent doses were administered only if a given patient dropped below a PASI90 response. Primary outcome was the percentage of patients that achieved and maintained optimal skin control over time, defined as achieving a PASI90 response.
Results:
Twenty-seven out of the 28 patients achieved a PASI90 response after the first two bimekizumab doses, and all maintained PASI90 responses with as-needed dosing over time. One patient achieved PASI90 after a single dose of bimekizumab, and voluntarily decided not to receive a second dose. No adverse events were observed.
Conclusions:
Larger prospective studies comparing efficacy and safety of this off-label, as needed, bimekizumab dosing regimen with standard on-label dosing are necessary to corroborate these findings.
Insights
This study explored an off-label, as-needed dosing strategy for bimekizumab in psoriasis patients. The results show high efficacy in maintaining PASI90 response with no observed adverse events.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis treatment has advanced, yet studies on off-label dosing of biologic therapies remain scarce.
- Biologic therapies offer significant benefits for moderate-to-severe psoriasis.
Purpose of the Study:
- To evaluate the efficacy and safety of an off-label, as-needed bimekizumab dosing regimen for moderate-to-severe psoriasis.
- To assess the maintenance of optimal skin control (PASI90 response) over time with this dosing strategy.
Main Methods:
- Retrospective case series of 28 patients with moderate-to-severe psoriasis treated with bimekizumab over 64 weeks.
- Off-label, as-needed dosing strategy initiated with two doses at Weeks 0 and 4, with subsequent doses based on maintaining PASI90 response.
Main Results:
- Twenty-seven of 28 patients achieved PASI90 response after initial bimekizumab doses.
- All patients maintained PASI90 response throughout the study period with as-needed dosing.
- No adverse events were reported during the study.
Conclusions:
- An off-label, as-needed bimekizumab dosing strategy appears effective for maintaining PASI90 response in psoriasis patients.
- Further prospective studies are needed to compare this regimen with standard on-label dosing.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...